Fosun Pharma: Henlius HLX17 receives U.S. FDA approval for clinical trials

Henlius HLX17 receives U.S. FDA approval for clinical trials

September 9, 2025 Source: drugdu 92

Fosun Pharma announced on the evening of September 8th that its controlling subsidiary, Shanghai Henlius Biotech Co., Ltd., and its subsidiaries (collectively, " Henlius "), have recently received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial of HLX17 (a recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of patients with various resected solid tumors. Henlius intends to conduct this international, multicenter clinical study in the United States once conditions permit.
https://finance.eastmoney.com/a/202509083507723471.html